The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Vanda Pharmaceuticals’ expansion into the booming GLP-1 market has cleared a midphase test. | Vanda Pharmaceuticals’ ...

Novo Nordisk announced Monday that it is significantly cutting the prices of its blockbuster GLP-1 drugs, Wegovy (for weight ...

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month ...

Major stock indexes ended sharply lower to begin the week, which will see AI darling Nvidia and retail giants report ...

Bitcoin just erased all of its gains for this year — and some analysts say more turbulence could be in store for the ...

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

Novo Nordisk announced that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients.

Good news for consumers battling the high cost of weight loss drugs. Novo Nordisk, the maker of Wegovy and Ozempic, announced ...

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to ...